Almirall’s 16th Skin Academy Unites Experts to Advance Dermatology
Almirall, a global pharmaceutical company specializing in medical dermatology, is hosting the 16th edition of its prestigious Skin Academy. This annual event serves as a premier conference for healthcare professionals in dermatology, offering a comprehensive program designed to share cutting-edge scientific knowledge on skin diseases, innovative treatments, and best clinical practices.
A Platform for Collaboration and Innovation
The Skin Academy provides a unique opportunity for professionals to collaborate, bringing together leading experts and clinicians from around the world. By fostering discussions and facilitating knowledge-sharing, the event plays a pivotal role in advancing dermatological care. Participants engage in dialogues that lead to the co-creation of innovative approaches, addressing the unmet needs of millions living with skin conditions.
According to Prof. Dr. Ulrich Mrowietz from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kiel in Germany, “Deep collaboration among experts is essential for advancing medical dermatology and improving patient outcomes. Almirall’s Skin Academy offers a unique platform for practitioners to explore the latest scientific advances and clinical practices. The event emphasizes holistic, personalized patient care and overall wellbeing.”
Dr. Volker Koscielny, Chief Medical Officer at Almirall, echoed this sentiment, stating, “This 16th edition of the Skin Academy underscores our commitment to providing a leading platform for exchange and advancement in medical dermatology. Our partnerships with the dermatology community across Europe are rooted in our focus on medical dermatology, bolstered by strong R&D capabilities and robust collaborations. This conference fosters innovative approaches that help address the pressing needs of millions affected by skin conditions.”
The Evolution of Almirall’s Skin Academy
The Skin Academy, initiated and sponsored by Almirall, has evolved into a cornerstone event for medical dermatology professionals. Over the years, it has become an essential platform for sharing state-of-the-art scientific knowledge and clinical best practices related to a wide range of skin diseases. The 16th edition continues this tradition, drawing over 800 participants led by international experts. Attendees engage in discussions aimed at advancing knowledge, enhancing patient care, and fostering a network of professionals dedicated to dermatological excellence.
Focus on Atopic Dermatitis
A central theme of this year’s conference is atopic dermatitis, a prevalent and often debilitating skin condition. Experts will share insights into the condition’s pathophysiology, including the role of IL-13 in its development. The event will also highlight advanced treatment protocols, providing a comprehensive analysis of the efficacy and safety of various treatments over time.
Additionally, discussions will address real-world evidence from clinical practice, exploring the effectiveness of existing therapies. A key area of focus is the dermatologist-patient relationship, emphasizing the importance of shared decision-making in treatment planning to ensure optimal patient outcomes.
Advances in Psoriasis Treatment
Psoriasis, another major focus of the 16th Skin Academy, will be explored through dedicated sessions on biologic treatments. These sessions will examine the unmet medical needs of psoriasis patients and the importance of personalized treatment plans for long-term disease control. Experts will share real-world evidence demonstrating the safety and effectiveness of IL-23 inhibitors and discuss the significance of prioritizing patient wellbeing as a treatment outcome.
Additionally, discussions will address the challenges of treating difficult-to-manage areas of the skin, such as the scalp. Given that scalp psoriasis affects between 40-90% of psoriasis patients, experts will explore advancements in topical treatments and new data on IL-23 inhibition, highlighting promising treatment approaches for this common condition.
Addressing Actinic Keratosis
Another critical topic at the conference is actinic keratosis (AK), a condition that requires early intervention to prevent progression to squamous cell carcinoma. Experts will discuss advancements in AK treatment, real-world clinical data, and the role of patient satisfaction in treatment adherence and outcomes. The event will also emphasize the importance of a strong physician-patient relationship, a key factor in the successful management of chronic skin diseases.
Other Dermatological Conditions
Beyond atopic dermatitis, psoriasis, and AK, the conference will address several other significant dermatological conditions, including:
- Androgenetic alopecia – discussions on the latest research and treatment options.
- Onychomycosis – insights into effective antifungal therapies.
- Chronic spontaneous urticaria – examination of innovative management strategies.
The event will feature poster sessions, clinical case discussions, and interactive Q&A segments with leading dermatology experts, ensuring an engaging and informative experience for all attendees.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. Through close collaborations with scientists, healthcare professionals, and patients, Almirall is committed to transforming patients’ lives by delivering innovative treatments that address their needs.
Founded in 1944 and headquartered in Barcelona, Almirall is publicly traded on the Spanish Stock Exchange under the ticker ALM. In 2024, the company reported total revenues of €990 million and employed over 2,000 professionals worldwide. Almirall’s products are available in more than 100 countries, improving the quality of life for countless patients every day.
The 16th Skin Academy reaffirms Almirall’s dedication to dermatological innovation and education. By providing a dynamic platform for experts to share knowledge and collaborate, the event continues to push the boundaries of medical dermatology, ultimately improving treatment options and patient outcomes across the globe.
